Abstract

Although diesel airborne particulate matter (PM2.5) has been known to play a role in many human diseases, there is no direct evidence that therapeutic drugs or proteins can diminish PM2.5‐induced diseases. Nevertheless, studies examining the negative control mechanisms of PM2.5‐induced diseases are critical to develop novel therapeutic medications. In this study, the consensus PDZ peptide of ZO‐1 inhibited PM2.5‐induced inflammatory cell infiltration, pro‐inflammatory cytokine gene expression, and TEER in bronchoalveolar lavage (BAL) fluid and AM cells. Our data indicated that the PDZ domain in ZO‐1 is critical for regulation of the PM2.5‐induced inflammatory microenvironment. Therefore, the PDZ peptide may be a potential therapeutic candidate during PM‐induced respiratory diseases.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call